Tag:

Gilead Sciences

Latest Headlines

Latest Headlines

33 indicted for selling BMS' Abilify, Novartis' Gleevec in massive diversion scheme

Federal authorities have rounded up nearly three dozen people indicted in a far-ranging scheme in which they allegedly sold $200 million worth of diverted drugs that included blockbusters like Bristol-Myers Squibb's antipsychotic Abilify, Gilead Sciences' HIV med Truvada and Novartis' cancer drug Gleevec.

AdverseEvents: New generation of hep C meds bests older therapies in side-effect reports

A new generation of hep C therapies could offer key safety advantages over older treatments, as a recent analysis by healthcare informatics firm AdverseEvents found that Gilead Sciences' Sovaldi and Harvoni were linked to fewer serious side effects in postmarketing data.

Gilead jumps into epigenetics with a bite-size biotech buyout

As market watchers wonder whether Gilead Sciences is on the verge of a blockbuster buyout, the Big Biotech inked a small deal that will beef up its efforts in the growing field of epigenetics.

Mylan launches Sovaldi in India, easing CL concerns

Generic drug companies Dr Reddy's Laboratories and Natco Pharma gained more than 2% on Monday as Mylan said its Indian unit will start sales of Gilead Sciences' Sovaldi (sofosbuvir 400) in India, a move that diminishes the likelihood of compulsory licensing of the drug as generic copies have already been licensed to local companies.

Gilead ready to take the cash from hep C superstars and buy something

Gilead Sciences brushed aside any concerns about the effects of discounting of superseller hepatitis C drugs Sovaldi and Harvoni by blasting past analysts' earnings estimates of how much the drugs would sell, total revenues, earnings per share, and just about any other measure the markets could dig up. And flush with cash, Gilead execs say, it just may be time to go out and buy some stuff.

Gilead's 'open to suggestion' on its next big M&A splash

On pace to reap $29 billion in revenue this year thanks to its surging hepatitis C franchise, Gilead Sciences has the cash to pull off a big deal or two, and management is eyeing a slew of late-stage opportunities.

Gilead plans Israel marketing office to remain with NewPharm drug chain

Gilead Sciences reportedly plans to open a marketing office in Israel where it sells its products through NewPharm, an Israel drug store chain.

Merck and Gilead square off in battle of the next-next-gen hep C combos

Early today both Gilead and Merck issued new data on their next-next-gen hepatitis C combos, demonstrating just how brutal the competition for market share is becoming while highlighting some of the boundaries that are emerging in shortening treatment regimens.

Does a $45B Vertex buyout make sense for Gilead? Porges says heck yes

Bernstein's Geoffrey Porges has run the numbers on what a Gilead takeover of Vertex would look like. And he loves what he sees.

States limit access to hep C meds amid pricing battle

As hep C drugmakers such as Gilead Sciences and AbbVie continue to duke it out for dominance, there is one piece of the market both sides are battling to claim: state Medicaid programs.